Long-term Follow-up of Nivolumab and Ipilimumab- (as Monotherapy and as Combination Therapy)-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR)

Study identification

• EU PAS number:
  EUPAS29722
• Study ID:
  39387
• Official title and acronym:
  Long-term Follow-up of Nivolumab and Ipilimumab- (as Monotherapy and as Combination Therapy)-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR)
• DARWIN EU® study:
  No
• Study countries:
  Netherlands
• Study description:
  No information provided.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Dutch Melanoma Treatment Registry (DMTR)

Study timelines

Date when funding contract was signed

Planned:28/06/2019

Actual:12/08/2019

Study start date

Planned:28/06/2019

Actual:28/06/2019

Date of final study report

Planned:31/12/2033

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb Company

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)